心血管疾病中eEF2K的药理向:机制和潜在的临床应用
Aysa Rezabakhsh1, Solomon Habtemariam2, Elnaz Khani3
1Cardiovascular Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
European journal of pharmacology
|October 18, 2025
概括
细胞延长因子2激酶 (eEF2K) 在心血管疾病 (CVD) 中起着双重作用. 针对eEF2K提供了治疗潜力,但需要对选择性调节器和生物标志物的进一步研究.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 心血管研究研究心血管研究
背景情况:
- 细胞延长因子2激酶 (eEF2K) 调节蛋白质合成和细胞能量保存.
- eEF2K与细胞对压力的反应有关,包括营养缺乏和缺氧.
- 虽然在癌症和神经退行方面进行了研究,但eEF2K在心血管疾病 (CVD) 中的作用越来越被认可.
研究的目的:
- 审查eEF2K的结构和监管方面.
- 检查eEF2K对心肌细胞存活,自,线粒体功能和心血管疾病中的内皮功能的影响.
- 探索针对eEF2K治疗心血管疾病的治疗潜力和挑战.
主要方法:
- 对eEF2K在心血管病理生理学中的作用的文献综述.
- 对eEF2K调制 (抑制和激活) 的临床前研究分析.
- 检查eEF2K与关键信号通路 (SIRT,AMPK,mTORC1) 和细胞过程 (自,线) 的相互作用.
主要成果:
- eEF2K调节影响心肌细胞存活,自,线粒体质量控制和内皮功能.
- 在临床前心血管疾病模型中,eEF2K的药理抑制显示出有前途,改善了血管重塑和血液动力学.
- 激活eEF2K可能会通过自和代谢适应来防止缺血性损伤.
- 调节eEF2K影响SIRT,AMPK,mTORC1和自/髓流,可能保护心血管细胞.
结论:
- eEF2K在心血管疾病中表现出双重的,取决于背景的角色.
- 针对eEF2K是一个复杂但有前途的心血管疾病治疗策略.
- 需要进一步的研究来开发选择性的eEF2K调节器,生物标志物,并进行临床试验.
相关概念视频
01:27Transducer Mechanism: Enzyme-Linked Receptors
3.9K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
3.9K
01:30Heart Failure V: Medical Management
215
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
215
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
928
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
928
01:26Targets for Drug Action: Overview
10.0K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
10.0K
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
436
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
436
02:38Mitogens and the Cell Cycle
7.7K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.7K